Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin - 30/11/11
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Background |
Heparanase degradation of heparan sulfate plays important roles in a number of pathological processes, including inflammation. In vitro experiments show that heparanase is capable of degrading heparin, a polysaccharide present in mast cells (MCs), in which it has a key role in promoting the storage of secretory granule compounds.
Objective |
We sought to investigate the functions of heparanase in MCs.
Methods |
Primarily cultured fetal skin-derived mast cells (FSMCs) isolated from embryos and adult peritoneal MCs were analyzed for storage and release of granule molecules in response to MC activation.
Results |
FSMCs from heparanase-overexpressing mice contained substantially shorter heparin chains and significantly less proteases than control cells. Conversely, FSMCs lacking heparanase contained heparin of larger size and more proteases than control cells. Correspondingly, heparanase-overexpressing adult MCs exhibited reduced release of heparin-bound proteases, a finding that could be attributed to spontaneous release of granular compounds. Heparanase was found to be upregulated in MCs on activation.
Conclusion |
These findings reveal a novel function of heparanase in maintaining MC homeostasis through controlled degradation of heparin present in the MC secretory granules.
Le texte complet de cet article est disponible en PDF.Key words : Mast cell, heparin, heparanase, protease, allergy
Abbreviations used : CPA, CTMC, DAPI, DNP, FACS, FITC, FSMC, GAG, GAPDH, hpa-KO, hpa-tg, HS, MC, MMC, mMCP, PMA
Plan
Supported by the Swedish Medical Research Council (K2009-67X-21128-01-3), the Swedish Cancer Research Foundation (09 0717), the Polysackaridforskning Foundation (Uppsala, Sweden), and National Institutes of Health grant CA106456 (I.V.). |
|
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest. |
Vol 128 - N° 6
P. 1310 - décembre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?